Literature DB >> 6189933

Analysis of T cell hybridomas. IV. Characterization of inducible suppressor cell hybridomas.

M Minami, K Okuda, S Furusawa, M E Dorf.   

Abstract

The Ts3 subset of suppressor cells is generated after antigen priming, but, in order to express suppressor activity these cells require an additional activation step involving triggering with specific suppressor factors (TsF2). This report characterizes two cloned hybridoma cell lines (pTs3 hybridomas) that represent this stage of Ts3 cell differentiation. These hybridoma cells could be specifically activated with TsF2 to release another antigen-specific suppressor factor (TsF3) within 6 h. The inducible feature of these cells permitted analysis of the signals necessary for Ts3 activation. Antigen was not required for activation. Only TsF2 factors derived from antiidiotypic second-order suppressor cells could activate pTs3 hybridoma cells. There were stringent genetic restrictions on the ability of Ts2 to activate pTs3 cells. Triggering of pTs3 required corecognition of two determinants on the TsF2 molecular complex, i.e., the I-J and Igh-related idiotypic determinants. Thus, although pTs3 cells could absorb TsF2 from an I-J-mismatched source, these pTs3 were not activated by the allogeneic TsF2. For activation to occur, the H-2 (I-J) and Igh complexes of the TsF2 donor had to match those of the strain from which the pTs3 cells were derived. Mixing two distinct TsF2, one derived from an H-2-matched source and the other from an Igh-matched source, failed to activate pTs3 cells. Once activated, the pTs3 cells released a suppressive material that was indistinguishable from the TsF3 factors previously characterized in this system. Finally, the activation of the pTs3 cells apparently does not induce the de novo synthesis of TsF3 since the suppressive activity could be extracted from nonactivated pTs3 cells. Thus, the inducible pTs3 hybridomas represent a mature stage in the differentiation cycle of Ts3 cells and provide a means for studying the nature of the specific signals required for Ts3 activation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6189933      PMCID: PMC2187012          DOI: 10.1084/jem.157.5.1379

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  28 in total

Review 1.  Antigen-specific, proliferating T lymphocyte clones. Methodology, specificity, MHC restriction and alloreactivity.

Authors:  B Sredni; R H Schwartz
Journal:  Immunol Rev       Date:  1981       Impact factor: 12.988

2.  Anti-receptor antibody-induced suppression of murine H-Y-specific delayed-type hypersensitivity responses.

Authors:  M E Sunday; J Z Weinberger; S Wolff; M E Dorf
Journal:  Eur J Immunol       Date:  1981-08       Impact factor: 5.532

3.  Functional association of idiotypic and I-J determinants on the antigen receptor of suppressor T cells.

Authors:  K Okuda; M Minami; S T Ju; M E Dorf
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

4.  Cross-induction of predominant NPb idiotypic antibodies with derivatives of (4-hydroxy-3-nitrophenyl) acetyl.

Authors:  S T Ju; M E Dorf
Journal:  J Immunol       Date:  1981-12       Impact factor: 5.422

5.  Differences in the ability of T cells to suppress the induction and expression of contact sensitivity.

Authors:  W R Thomas; M C Watkins; G L Asherson
Journal:  Immunology       Date:  1981-01       Impact factor: 7.397

6.  Presence of interchain disulfide bonds between two gene products that compose the secreted form of an antigen-specific suppressor factor.

Authors:  M Taniguchi; T Saito; I Takei; T Tokuhisa
Journal:  J Exp Med       Date:  1981-06-01       Impact factor: 14.307

7.  Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. VII. Idiotype-specific suppression of plaque-forming cell responses.

Authors:  D H Sherr; S T Ju; J Z Weinberger; B Benacerraf; M E Dorf
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

8.  Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. IX. Characterization of Idiotype-specific effector-phase suppressor cells on plaque-forming cell responses in vitro.

Authors:  D H Sherr; M E Dorf
Journal:  J Exp Med       Date:  1981-06-01       Impact factor: 14.307

9.  Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. XI. Pseudogenetic restrictions of hybridoma suppressor factors.

Authors:  K Okuda; M Minami; D H Sherr; M E Dorf
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

10.  Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. VIII. Suppressor cell pathways in cutaneous sensitivity responses.

Authors:  M E Sunday; B Benacerraf; M E Dorf
Journal:  J Exp Med       Date:  1981-04-01       Impact factor: 14.307

View more
  5 in total

1.  The control of the contact sensitivity skin reaction: T-suppressor afferent cell blocks the production of antigen-specific T-helper factor.

Authors:  G L Asherson; V Colizzi; B M James
Journal:  Immunology       Date:  1985-03       Impact factor: 7.397

2.  Molecular genetic characterization of the mRNA coding for an inducible suppressor factor specific for L-glutamic acid60-L-alanine30-L-tyrosine10.

Authors:  C L Funckes-Shippy; C M Sorensen; C W Pierce; A D Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

3.  Antigen-specific, I-A-restricted suppressor hybridomas with spontaneous cytolytic activity. Functional properties and lack of rearrangement of the T cell receptor beta chain genes.

Authors:  C A Blanckmeister; K Yamamoto; M M Davis; G J Hämmerling
Journal:  J Exp Med       Date:  1985-09-01       Impact factor: 14.307

4.  The role of I-J and Igh determinants on F1-derived suppressor factor in controlling restriction specificity.

Authors:  M Minami; I Aoki; N Honji; C R Waltenbaugh; M E Dorf
Journal:  J Exp Med       Date:  1983-11-01       Impact factor: 14.307

5.  Acceptor-suppressor T cell hybridoma with a receptor recognizing antigen-specific suppressor factor.

Authors:  I Takei; T Sumida; M Taniguchi
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.